Jazz Pharmaceuticals plc announced that its GAAP and non-GAAP financial results for the third quarter of 2026 are estimated to include a pre-tax charge of approximately $755 million of acquired in-process research and development expense. This charge is associated with the compan

Jazz Pharmaceuticals plc Estimates $755 Million Q3 Financial Impact from Actio Biosciences Acquisition

(RTTNews) - Friday, Jazz Pharmaceuticals plc (JAZZ) announced updated overall survival results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera in combination with chemotherapy, with or without Tevimbra for the treatment of adults with HER2-positive locally advanced or me

Jazz Pharmaceuticals Reports Positive Phase 3 Results For Ziihera Combination 

The S&P 500 Index ($SPX ) (SPY ) closed up by +0.38% on Tuesday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up by +1.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.13%.  December E-mini S&P futures (ESZ26 ) rose +0.33%, and December E-mini...

Stocks Finish Mostly Higher on Earnings Optimism

The S&P 500 Index ($SPX ) (SPY ) is up by +0.60% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +1.23%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.12%.  December E-mini S&P futures (ESZ26 ) are up +0.60%, and December E-mini...

Stocks Rebound on Strong Earnings and Lower Bond Yields

The S&P 500 Index ($SPX ) (SPY ) is down by -0.15% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +0.57%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.82%.  December E-mini S&P futures (ESZ26 ) are down -0.10%, and December E-mini...

Stocks Pressured by Tech Stock Weakness and Higher Crude Oil Prices

The S&P 500 Index ($SPX ) (SPY ) closed up by +0.33% on Thursday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up by +1.08%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.05%.  December E-mini S&P futures (ESZ26 ) rose +0.28%, and December E-mini...

Stocks Settle Mixed as Broader Market Recovers from Chip Stock Rout

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals plc News